MK-5172 in Combination with MK-8742 in Subjects with HCV/HIV Co-Infection

Registry ID

EUCTR2014-000342-30

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc

Start date

2014-05-19

Completion date

2015-05-22

Last update

2026-08-16

Conditions

• Hepatitis C

Summary

1. To evaluate the efficacy of MK-5172 in combination with MK-8742 as assessed by the proportion of subjects achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy), defined as HCV RNA <LLOQ (either TD[u] or TND) 12 weeks after the end of all study therapy 2. To evaluate the safety and tolerability of MK-5172 in combination with MK-8742

Locations

• , , Spain
• , , Denmark

Related clinical trials

• Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV
• Evaluation of Patients With Liver Disease
• The Australian HCV Point-of-Care Testing Program
• Project I Test: Implementing HIV Testing in Opioid Treatment Programs
• The National Australian HCV Point-of-Care Testing Program - Minimal Dataset
• The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset

View on source registry